1. Home
  2. CGEM vs EQBK Comparison

CGEM vs EQBK Comparison

Compare CGEM & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$11.44

Market Cap

999.4M

Sector

Health Care

ML Signal

N/A

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

N/A

Current Price

$48.94

Market Cap

982.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
EQBK
Founded
2016
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
999.4M
982.9M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
CGEM
EQBK
Price
$11.44
$48.94
Analyst Decision
Strong Buy
Buy
Analyst Count
12
7
Target Price
$34.60
★ $54.14
AVG Volume (30 Days)
★ 720.7K
128.1K
Earning Date
11-17-2026
10-14-2026
Dividend Yield
N/A
★ 1.80%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 2.06
Revenue
N/A
N/A
Revenue This Year
N/A
$29.42
Revenue Next Year
$300.03
$21.36
P/E Ratio
★ N/A
$24.26
Revenue Growth
N/A
★ N/A
52 Week Low
$7.25
$40.22
52 Week High
$23.19
$52.27

Technical Indicators

Market Signals
Indicator
CGEM
EQBK
Relative Strength Index (RSI) 33.19 53.15
Support Level N/A $48.53
Resistance Level $16.31 $51.93
Average True Range (ATR) 1.19 1.09
MACD -0.22 0.14
Stochastic Oscillator 12.69 44.49

Price Performance

Historical Comparison
CGEM
EQBK

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

Share on Social Networks: